NEWS HIGHLIGHTSMedia Articles Related to Zomig Nasal (Zolmitriptan)
Migraine Raises Risk Of Most Common Form Of Stroke
Source: Headache / Migraine News From Medical News Today [2009.11.17]
Pooling results from 21 studies, involving 622,381 men and women, researchers at Johns Hopkins have affirmed that migraine headaches are associated with more than twofold higher chances of the most common kind of stroke: those occurring when blood supply to the brain is suddenly cut off by the buildup of plaque or a blood clot. The risk for those with migraines is 2.3 times those without, according to calculations from the Johns Hopkins team, to be presented Nov.
Migraine Increases Likelihood of Stroke
Source: MedicineNet Birth Control Specialty [2009.11.17]
Title: Migraine Increases Likelihood of Stroke
Category: Health News
Created: 11/16/2009 12:10:00 PM
Last Editorial Review: 11/17/2009
Molecular Imaging Pinpoints Inflammation In The Brains Of Schizophrenics And Migraine Sufferers
Source: Headache / Migraine News From Medical News Today [2009.11.02]
Inflammatory response of brain cells - as indicated by a molecular imaging technique - could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of The Journal of Nuclear Medicine.
Migraine With Aura Is Associated With Increased Risk Of Stroke
Source: Headache / Migraine News From Medical News Today [2009.10.29]
A migraine with aura occurs when temporary visual or sensory disturbances are experienced before or during a migraine headache. A study just published on bmj.com reports that migraine with aura is associated with a twofold increased risk of stroke. Further risk factors for stroke among patients with migraine are being a woman, being young, being a smoker, and using contraceptives containing estrogen.
Migraine With Aura Doubles The Risk Of Stroke
Source: Headache / Migraine News From Medical News Today [2009.10.28]
Migraine with aura (temporary visual or sensory disturbances before or during a migraine headache) is associated with a twofold increased risk of stroke, finds a study published on bmj.com today. Further risk factors for stroke among patients with migraine are being a woman, being young, being a smoker, and using oestrogen containing contraceptives.
Published Studies Related to Zomig Nasal (Zolmitriptan)
Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. [2009.07]
Neuroleptic-induced akathisia (NIA) is a common, sometimes incapacitating adverse effect of anti-psychotic medication... Further placebo-controlled studies are warranted.
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. [2008.12.20]
BACKGROUND: Calcitonin gene-related peptide (CGRP) probably has a role in migraine pathophysiology, and antagonism of its receptors might provide treatment without the vasoconstrictor effects of triptans. We aimed to assess the clinical profile of MK-0974 (telcagepant), an orally bioavailable antagonist of CGRP receptor... INTERPRETATION: Telcagepant 300 mg is effective as an acute treatment for migraine with efficacy comparable to that of zolmitriptan 5 mg, but with fewer associated adverse effects. FUNDING: Merck Research Laboratories.
Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. [2007.08.28]
OBJECTIVE: To evaluate the efficacy and tolerability of zolmitriptan 5 mg and 10 mg nasal spray (ZNS) vs placebo in the acute treatment of cluster headache...
Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. [2006.11]
BACKGROUND: Cluster headache is a form of primary headache in which attacks are rapid in onset with very severe pain. The mainstays of acute therapy are inhaled oxygen and sumatriptan succinate injection. OBJECTIVE: To evaluate zolmitriptan nasal spray in the acute treatment of cluster headache... CONCLUSION: Five-milligram and 10-mg doses of zolmitriptan intranasal spray are effective within 30 minutes and well tolerated in the treatment of acute cluster headache. Trial Registration controlled-trials.com Identifier ISCRTN27362692.
Effectiveness of Intranasal Zolmitriptan in Acute Cluster Headache: A Randomized, Placebo-Controlled, Double-blind Crossover Study. [2006.09.11]
BACKGROUND: Cluster headache is a form of primary headache in which attacks are rapid in onset with very severe pain. The mainstays of acute therapy are inhaled oxygen and sumatriptan succinate injection. OBJECTIVE: To evaluate zolmitriptan nasal spray in the acute treatment of cluster headache... CONCLUSION: Five-milligram and 10-mg doses of zolmitriptan intranasal spray are effective within 30 minutes and well tolerated in the treatment of acute cluster headache.Trial Registration controlled-trials.com Identifier ISCRTN27362692.Published online September 11, 2006 (doi:10.1001/archneur.63.11.nct60002).
Clinical Trials Related to Zomig Nasal (Zolmitriptan)
ZAP, US. Zomig for Appropriate for Primary Care [Completed]
The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™
(zolmitriptan) 5. 0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5. 0 mg is for patients, in
treating migraine over a period of 6 months
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents [Completed]
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig)
nasal spray, 5. 0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a
3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
Efficacy and Tolerability of Zolmitriptan Nasal Spray [Completed]
The purpose of this study is to evaluate the effectiveness and tolerability (the ability not
to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5. 0 mg,
compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult
subjects with migraine headaches
MK0974 Pivotal Study 1 - WW (With Active Comparator) [Completed]
|
